Eli Lilly and Company (LLY)
SIX Swiss Exchange · Switzerland · prices in CHF · close of 22 Oct 2026
Key indicators
| Last close | CHF 1,080.00 |
|---|---|
| 52-week range | 640.00 – 1,080.00 |
| Return, 1 month / 3 months | +11.9% / +13.8% |
| Return, 1 year / 3 years | +69.8% / +104.3% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 39.6% |
| Worst drawdown (1 year) | -24.3% |
| Average daily value traded | 0.00M CHF |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eli Lilly and Company is a pharmaceutical company based in Indianapolis in the United States. It researches, develops and manufactures prescription medicines for people with conditions such as diabetes, obesity, cancer, immune disorders and mental health problems. Its products include insulin treatments and other branded drugs, and it supplies them to hospitals, doctors, pharmacies and patients in many countries around the world through wholesale and distribution channels.
The shares are listed on the SIX Swiss Exchange in Switzerland under the code LLY, and the price on this page is in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eli Lilly and Company (LLY) trades on the SIX Swiss Exchange in Switzerland. It last closed at CHF 1,080.00 on 22 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 94 of 225 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 69.8% and over the last three months it rose 13.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on SIX Swiss Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.3% | ||
| From 52-week high | 0.0% | ||
| Momentum | 87 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 13.8% | ||
| 6-month return | 51.5% | ||
| 12-month return, skipping the last month | 51.8% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.3% | ||
| Liquidity | 3 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M CHF | ||
| Zero-volume days | 78.3% | ||
| Income | 30 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.9% |
|---|---|
| 1 month | +11.9% |
| 3 months | +13.8% |
| 6 months | +51.5% |
| 1 year | +69.8% |
| 3 years | +104.3% |
| 5 years | +444.1% |
Signals
| 50-day / 200-day average | 974.77 / 869.14 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 39.96 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | USD 1.4038 |
| 13 May 2026 | USD 1.3538 |
| 13 Feb 2026 | USD 1.3324 |
| 14 Nov 2025 | USD 1.1901 |
| 15 Aug 2025 | USD 1.2079 |
| 16 May 2025 | USD 1.2588 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on SIX Swiss Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.